Indication: Relapsing MS
Title: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)
Purpose: International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
For details go to Clinical Trials.gov
Title: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Purpose: The purpose of this study is to compare 2 doses (0.25 mg and 0.50 mg) of fingolimod to glatiramer acetate (20 mg) and to evaluate the efficacy of fingolimod 0.25 mg for the treatment of patients with relapsing-remitting MS (RRMS).
For details go to Clinical Trials.gov
Indication: Primary Progressive MS
Title: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Purpose: This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
For details go to Clinical Trials.gov
Indication: Spasticity and MS
Title: Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis
Purpose: The purpose of this study is to assess whether baclofen ER capsules demonstrate efficacy and safety in the treatment of spasticity.
For details go to Clinical Trials.gov
Title: Action of Baclofen Capsules in Spasticity Due to Multiple Sclerosis
Purpose: This is a double-blind, randomized, placebo-controlled trial to evaluate duration of action of Baclofen ER capsules (GRS) compared with placebo in subjects with spasticity due to Multiple sclerosis.
For details go to Clinical Trials.gov
Indication: NMO
Title: Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Purpose: The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD
For details go to Clinical Trials.gov